Zota Health Care Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹143Cr
- +98.6% YoY
- +10.9% QoQ
- Net profit
- −₹30Cr
- Q3 FY25: −₹19 Cr
- Margin
- −0.3%
- +7.7 pp YoY
- −5.2 pp QoQ
Guidance rank: #6 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Mature stores in the first cohort (~4 years old) are growing at 15%-20% year-on-year, with revenues around INR7 lakh per month and potential to exceed INR1 crore per annum in 2 years. EBITDA margins are expected to improve significantly as stores mature; mature COCO stores can achieve EBITDA margins of 25%-30%, and overall company EBITDA margins could reach 15%-20% in 2-3 years if no new stores are added.
From Zota Health Care Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Mature stores in the first cohort (~4 years old) are growing at 15%-20% year-on-year, with revenues around INR7 lakh per month and potential to exceed INR1 crore per annum in 2 years.
- Gross margins have improved YoY from 55% to nearly 60%, driven by higher Davaindia revenue contribution.
- Planned aggressive expansion with 800-1,000 new COCO stores annually; next year's store addition to be more evenly phased (~200-250 per quarter).
- Footfalls at mature stores rising (80-100 daily customers for >2 years stores), with overall footfall stable despite new low-traffic stores.
2 more points from Zota Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Zota Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The INR 350 crore raised through the QIP is primarily being deployed towards Davaindia.
- Majority of the funds are used for new store expansions and working capital requirements within Davaindia.
- A smaller portion of the QIP funds is allocated to General Corporate Purposes.
- The company has incorporated a new wholly owned subsidiary, KMHP Ventures Limited, to engage in marketing and trading of pharmaceutical products, enhancing control over sourcing, distribution, and margin optimization.
- Additional equity has been infused in Davaindia Health Mart Limited to support COCO store expansion and working capital.
2 more points from Zota Health Care Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zota Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Zota Health Care Ltd's call on order book
Create a free account to keep reading this call
Zota Health Care Ltd — Quarterly revenue & net profit
Zota Health Care Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 143 | 72 | +98.6% | 129 | +10.9% |
| Operating profit (EBITDA) | -0 | -6 | — | 6 | -100% |
| Operating margin | -0.3% | -8% | +7.7 pp | 4.9% | -5.2 pp |
| Profit before tax | -26 | -18 | — | -14 | — |
| Net profit (PAT) | -30 | -19 | — | -16 | — |
| EPS (₹) | -8.73 | -6.78 | — | -5.20 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹199 Cr, net loss ₹26 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zota Health Care's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
Earlier calls (2)
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zota Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zota Health Care Ltd Q3 FY26 results?
Mature stores in the first cohort (~4 years old) are growing at 15%-20% year-on-year, with revenues around INR7 lakh per month and potential to exceed INR1 crore per annum in 2 years. EBITDA margins are expected to improve significantly as stores mature; mature COCO stores can achieve EBITDA margins of 25%-30%, and overall company EBITDA margins could reach 15%-20% in 2-3 years if no new stores are added.
What is Zota Health Care Ltd share price analysis?
Zota Health Care Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹3,918 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zota Health Care Ltd planning capital expenditure?
The INR 350 crore raised through the QIP is primarily being deployed towards Davaindia.
Keep Zota Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
